Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Domestic market and developing countries will need doses of Indian vaccines
_256_384.jpg)
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
Investment of Rs 235 crores to add 411 beds in the next 18 months
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Fitterfly has launched an online Prediabetes risk test which is an evidence-based, clinically validated tool for assessing an individual's risk of Prediabetes
Demand normalisation post the second wave contributed to the steady growth
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Subscribe To Our Newsletter & Stay Updated
